All Updates

All Updates

icon
Filter
Product updates
Natera introduces new feature for Prospera heart test for transplant patients
Precision Medicine
Jun 17, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 17, 2024

Natera introduces new feature for Prospera heart test for transplant patients

Product updates

  • Natera has introduced new features to its Prospera Heart test, aimed at improving the detection of rejection in heart transplant patients. The newest features of the test leverages the novel Donor Quantity Score (DQS) technique. DQS is a new metric that normalizes for the background total cfDNA, enhancing donor-derived cell-free DNA (dd-cfDNA) tests for more accurate risk assessment in transplant rejection cases.

  • DQS is combined with the traditional donor fraction in a two-threshold algorithm, providing a single risk analysis result for antibody-mediated rejection (AMR) and acute cellular rejection (ACR). The company claims this feature will help avoid unnecessary biopsies and follow-up procedures.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.